Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 75/100

Failure Rate

25.0%

1 terminated/withdrawn out of 4 trials

Success Rate

50.0%

-36.5% vs industry average

Late-Stage Pipeline

25%

1 trials in Phase 3/4

Results Transparency

0%

0 of 1 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 2
2(50.0%)
Phase 1
1(25.0%)
Phase 3
1(25.0%)
4Total
Phase 2(2)
Phase 1(1)
Phase 3(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (4)

Showing 4 of 4 trials
NCT05322954Phase 1Active Not Recruiting

Study of the Safety and Feasibility of Psilocybin in Adults With Methamphetamine Use Disorder

Role: collaborator

NCT04504734Phase 3Terminated

Bucillamine in Treatment of Patients With COVID-19

Role: lead

NCT02942420Phase 2Unknown

Bucillamine Phase 2 Trial in Patients With Cystinuria

Role: lead

NCT02330796Phase 2Completed

Bucillamine for the Treatment of Acute Gout Flare in Subjects With Moderate to Severe Gout

Role: lead

All 4 trials loaded